Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.
Link to Agencia SINC
Expansión, El Periódico de Catalunya and Diario de Córdoba, among other media, have published articles about the biotechnologist Iproteos, a company created in 2011 by the scientists Teresa Tarragó and Ernest Giralt and based on the transfer of a technology developed atIRB Barcelona and the University of Barcelona (UB). The company has launched a project to develop a therapeutic strategy, designed by IBEC, to treat solid tumours, which account for 90-95% of cancer cases.
The “Dinero” supplement of the newspaper La Vanguardia has interviewed Roger Gomis, ICREA researcher at IRB Barcelona, about Inbiomotion, a spin-off from the institute and ICREA. This company, which came about from biomedical research and an entrepreneurial spirit, develops and commercialises a diagnostic test that allows the identification of those breast cancer patients most likely to develop bone metastasis.
The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.
